Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer (China Cohort)

Trial Identifier: D081SC00001Sub
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Start Date: June 2021
Primary Completion Date: January 2024
Study Completion Date: April 2026
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100050
China Beijing, China, 100191
China Beijing, China, 100142
China Beijing, China, 100730
China Beijing, China, 100034
China Guangzhou, China, 510180
China Guangzhou, China, 510515
China Guizhou, China, 550002
China Henan, China, 450008
China Hubei, China, 430030
China Hunan, China, 410013
China Hunan, China, 410008
China Jilin, China, 130021
China Jilin, China, 130012
China Liaoning, China, 110001
China Nanchang, China, 330006
China Nanjing, China, 2100008
China Ningbo, China, 315000
China Shanghai, China, 200040
China Sichuan, China, 610072
China Sichuan, China, 610041
China Xian, China, 710061
China Zhejiang, China, 310009
China Zhejiang, China, 310014